chlorothiazide

Trade name: diuril

Small moleculeapproved

Approved

Sep 4, 1958

Like other thiazides, chlorothiazide promotes water loss from the body (diuretics). It inhibits Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. Chlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic efficacy. Chlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate. After oral doses, 10-15 percent of the dose is excreted unchanged in the urine. Chlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk. As a diuretic, chlorothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like chlorothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of chlorothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle. It is marketed under the brand name Diuril. — NCATS

Clinical trial activity

5 trials · 5 clinical orgs · 21 marketing orgs

Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
3

Earliest trial started Apr 1, 1966 (NCT00000484)

Timeline

1950s

  1. Sep 4, 1958

    Merck — Earliest FDA Approval

  2. Sep 4, 1958

    Akorn, Inc. — NDA Secondary Org

  3. Sep 4, 1958

    Merck — NDA Organization

  4. Sep 4, 1958

    Akorn, Inc. — Marketing Organization

  5. Sep 4, 1958

    Rising Pharmaceuticals — Marketing Organization

  6. Dec 11, 1958

    Merck — Marketing Organization

1960s

  1. Oct 6, 1961

    Salix — NDA Secondary Org

  2. Jan 1, 1966

    Earliest Phase 3 Sponsor(trial)

1970s

  1. Jul 17, 1975

    PHARMOBEDIENT — Marketing Organization

  2. Nov 4, 1977

    Watson Pharmaceuticals — Marketing Organization

  3. Mar 8, 1978

    AmerisourceBergen — Marketing Organization

1980s

  1. Apr 1, 1981

    Sandoz — Marketing Organization

  2. Jul 14, 1982

    Hikma — Marketing Organization

  3. Sep 2, 1982

    Lederle — Marketing Organization

  4. Sep 2, 1982

    American Cyanamid — Marketing Organization

2000s

  1. Oct 16, 2009

    Fresenius — Marketing Organization

2010s

  1. Jul 26, 2011

    Sun Pharmaceuticals — Marketing Organization

  2. Apr 22, 2013

    Lutipold — Marketing Organization

  3. Apr 22, 2013

    Sankyo — Marketing Organization

  4. Apr 22, 2013

    Daiichi Sankyo — Marketing Organization

  5. Jun 18, 2014

    Mylan — Marketing Organization

  6. Jun 18, 2014

    Apicore — Marketing Organization

  7. May 29, 2015

    Sagent Pharmaceuticals, Inc. — Marketing Organization

2020s

  1. Oct 3, 2024

    Gland Pharma Ltd — Marketing Organization

Indications

Mechanism of action

Combination products

Approval history

  • approvedPriority reviewSep 4, 1958

Chemistry & pharmacology

Loading structure…

SMILES

NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O
Mol. weight
295.73 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral, Parenteral
Availability
Prescription Only

Oral

Yes

Parenteral

Yes

Topical

No

Sources

Also known as

  • 6-chloro-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[1,2,4]thiadiazine-7-sulfonic acid amide
  • 6-chloro-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[1,2,4]thiadiazine-7-sulfonic acid amide
  • 6-chloro-7-sulfamoyl-2h-1,2,4-benzothiadiazine 1,1-dioxide
  • 6-chloro-7-sulfamoyl-2h-1,2,4-benzothiadiazine 1,1-dioxide
  • chlorothiazid
  • chlorothiazid
  • chlorothiazide
  • chlorothiazide
  • chlorothiazide
  • chlorothiazide
  • chlorothiazide
  • chlorothiazide
  • chlorothiazide
  • chlorothiazide
  • chlorothiazide
  • chlorothiazide
  • chlorothiazide
  • chlorothiazide sodium
  • chlorothiazide sodium
  • chlorothiazide sodium
  • chlorothiazide sodium
  • chlorothiazidum
  • chlorothiazidum
  • chlorthiazide
  • chlorthiazide
  • chlorthiazide
  • clorotiazida
  • clorotiazida
  • diuril
  • diuril
  • diuril
  • mechlozid
  • mechlozid
  • saluric
  • saluric
  • uroflux
  • uroflux

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03574857Phase 4Jun 30, 2018University of Virginia
NCT02606253Phase 4Feb 1, 2016Vanderbilt University
NCT02546583N/AAug 1, 2015Yale University
NCT05840536Phase 4May 31, 2014Ochsner Health System
NCT00000484Phase 3Apr 1, 1966National Heart, Lung, and Blood Institute (NHLBI)
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Heart, Lung, and Blood Institute (NHLBI)Government1111966
Ochsner Health SystemAcademic/Hospital1112014
University of VirginiaAcademic/Hospital1112018
Vanderbilt UniversityAcademic/Hospital1112016
Yale UniversityAcademic/Hospital1112015
5 organizations
Page 1 / 1

Marketing (28)

OrganizationOrg typeRelationshipDate
Akorn, Inc.For profitNDA2Sep 4, 1958
Akorn, Inc.For profitMKTGSep 4, 1958
American CyanamidFor profitMKTGSep 2, 1982
AmerisourceBergenFor profitMKTGMar 8, 1978
ApicoreFor profitMKTGJun 18, 2014
Daiichi SankyoFor profitMKTGApr 22, 2013
FreseniusFor profitMKTGOct 16, 2009
Gland Pharma LtdFor profitMKTGOct 3, 2024
HikmaFor profitMKTGJul 14, 1982
HikmaFor profitSYNDec 22, 1983
HikmaFor profitSYNDec 22, 1983
LederleFor profitMKTGSep 2, 1982
LutipoldFor profitMKTGApr 22, 2013
MerckFor profitNDASep 4, 1958
MerckFor profitMKTGDec 11, 1958
MylanFor profitSYNJul 17, 1975
MylanFor profitMKTGJun 18, 2014
PHARMOBEDIENTFor profitMKTGJul 17, 1975
Par PharmaceuticalsFor profitMKTG
Rising PharmaceuticalsFor profitMKTGSep 4, 1958
Sagent Pharmaceuticals, Inc.For profitMKTGMay 29, 2015
Sagent Pharmaceuticals, Inc.For profitSYNMay 29, 2015
SalixFor profitNDA2Oct 6, 1961
SandozFor profitMKTGApr 1, 1981
SankyoFor profitMKTGApr 22, 2013
Sun PharmaceuticalsFor profitSYNJul 26, 2011
Sun PharmaceuticalsFor profitMKTGJul 26, 2011
Watson PharmaceuticalsFor profitMKTGNov 4, 1977